Annamaria Colao

Summary

Affiliation: Federico II University
Country: Italy

Publications

  1. ncbi Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 159:389-97. 2008
  2. ncbi The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs
    A Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Endocrinol Invest 26:53-6. 2003
  3. ncbi Medical consequences of acromegaly: what are the effects of biochemical control?
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131, Naples, Italy
    Rev Endocr Metab Disord 9:21-31. 2008
  4. ncbi Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:2112-8. 2006
  5. doi Resistance to somatostatin analogs in acromegaly
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, University Federico II, Naples, Italy
    Endocr Rev 32:247-71. 2011
  6. ncbi Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency
    A Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Nuclear Medicine Center of the National Council of Research, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 86:1874-81. 2001
  7. ncbi Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly
    A Colao
    Department of Molecular, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:4193-7. 2002
  8. ncbi The GH-IGF-I axis and the cardiovascular system: clinical implications
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy
    Clin Endocrinol (Oxf) 69:347-58. 2008
  9. ncbi Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 67:426-33. 2007
  10. ncbi The importance of presurgical somatostatin analogue therapy in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II
    Endokrynol Pol 58:356-60. 2007

Detail Information

Publications181 found, 100 shown here

  1. ncbi Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 159:389-97. 2008
    ..In the general population, low IGF1 has been associated with higher prevalence of cardiovascular disease and mortality...
  2. ncbi The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs
    A Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Endocrinol Invest 26:53-6. 2003
    ..In conclusion, more than 80% of patients with acromegaly unsuccessfully treated by surgery or currently available somatostatin analogs can achieve normal IGF-I levels after short-term treatment with pegvisomant...
  3. ncbi Medical consequences of acromegaly: what are the effects of biochemical control?
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131, Naples, Italy
    Rev Endocr Metab Disord 9:21-31. 2008
    ....
  4. ncbi Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:2112-8. 2006
    ..Primary treatment with depot octreotide and lanreotide induces tumor shrinkage in newly diagnosed patients with acromegaly...
  5. doi Resistance to somatostatin analogs in acromegaly
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, University Federico II, Naples, Italy
    Endocr Rev 32:247-71. 2011
    ..This latter evidence seems to occur in 25% of treated patients after 12 months of currently available long-acting SA...
  6. ncbi Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency
    A Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Nuclear Medicine Center of the National Council of Research, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 86:1874-81. 2001
    ....
  7. ncbi Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly
    A Colao
    Department of Molecular, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:4193-7. 2002
    ..45; P = 0.006). In conclusion, short-term GH and IGF-I suppression after surgery or LAN significantly increased T and DHT levels and improved sperm number and motility in acromegalic men...
  8. ncbi The GH-IGF-I axis and the cardiovascular system: clinical implications
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II, Naples, Italy
    Clin Endocrinol (Oxf) 69:347-58. 2008
    ..Both in GH deficiency (GHD) and excess life expectancy has been reported to be reduced because of cardiovascular disease...
  9. ncbi Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 67:426-33. 2007
    ..Remission rates of 76, 69.5 and 64.3% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2-5 years after cabergoline (CAB) withdrawal...
  10. ncbi The importance of presurgical somatostatin analogue therapy in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University of Naples Federico II
    Endokrynol Pol 58:356-60. 2007
    ..Somatostatin analogues also induce significant shrinkage of GH-secreting pituitary tumours, although this does not seem to be helpful in terms of improved surgical outcome...
  11. ncbi Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Clin Endocrinol (Oxf) 53:13-9. 2000
    ..Cushing's disease is characterized by abnormalities of immune function...
  12. doi Medical treatment of prolactinomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Italy, Via Sergio Pansini 5, I 80131 Naples, Italy
    Nat Rev Endocrinol 7:267-78. 2011
    ..This Review reports on efficacy and safety of pharmacotherapy in patients with prolactinomas...
  13. ncbi Severe systemic complications of acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Napoli, Italy
    J Endocrinol Invest 28:65-77. 2005
    ..There is still no demonstration that improvement of different complications corresponds a reduction in mortality...
  14. ncbi Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Napoli, Italy
    Clin Endocrinol (Oxf) 58:169-76. 2003
    ..Cardiovascular disease is the most frequent cause of death of patients with acromegaly...
  15. ncbi Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy)
    Annamaria Colao
    Dipartimento di Medicina Clinica e ChirurgiaSezione di Endocrinologia, Universita Federico II di Napoli, Via S Pansini 5, 80131 Naples, ItalyClinical Center of Endocrinology and Gerontology Akad Ivan Pentchev Medical University Sofia2 Zdrave Street, 1431 Sofia, BulgariaNew Bulgarian University21 Montevideo Street, 1618 Sofia, Bulgaria
    Eur J Endocrinol 171:263-73. 2014
    ..This retrospective, comparative, cohort study investigated the impact of different treatment modalities on disease control (GH and IGF1) and mortality in acromegaly patients...
  16. ncbi Lymphocyte subset pattern in acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Endocrinol Invest 25:125-8. 2002
    ..These data further support the existence of abnormalities of the immune system in patients with chronic GH/IGF-1 excess...
  17. ncbi Pituitary tumours: the prolactinoma
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Naples, Italy
    Best Pract Res Clin Endocrinol Metab 23:575-96. 2009
    ..The patients achieving disappearance of the tumours and suppression of PRL levels during treatment are those showing the highest likelihood to have persistent remission of hyperprolactinaemia after treatment withdrawal...
  18. ncbi First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II, University of Naples, Italy
    Clin Endocrinol (Oxf) 64:342-51. 2006
    ..The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor...
  19. ncbi [New therapeutic strategies in gastroenteropancreatic neuroendocrine tumours]
    A Colao
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Naples, Italy
    Minerva Endocrinol 26:231-8. 2001
    ....
  20. ncbi Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients
    A Colao
    Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Eur J Endocrinol 143:61-9. 2000
    ..The role of IGF-I in prostate development is currently under thorough investigation since it has been claimed that IGF-I is a positive predictor of prostate cancer...
  21. ncbi Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:1704-11. 2004
    ..These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas...
  22. ncbi Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 66:714-22. 2007
    ..Limited data are available on clinical presentation and treatment strategy in patients with GH-secreting adenomas with onset in adolescence...
  23. ncbi A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients
    A Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    J Endocrinol Invest 30:497-506. 2007
    ..We suggest that an accurate clinical check-up and, possibly, a more aggressive treatment of hypertension and diabetes are required in elderly acromegalics...
  24. ncbi Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Nuclear Medicine Center of the National Council of Research, Federico II University of Naples, Napoli, Italy
    J Clin Endocrinol Metab 84:1518-23. 1999
    ..abstract truncated)..
  25. ncbi First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Pansini 5, 80131 Napoli, Italy
    J Endocrinol Invest 29:1017-20. 2006
  26. doi Improvement of cardiac parameters in patients with acromegaly treated with medical therapies
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    Pituitary 15:50-8. 2012
    ..Selected patients with acromegaly should consider first-line therapy or pre-treatment with somatostatin analogues prior to surgery to achieve biochemical control and improve cardiac dysfunction...
  27. ncbi Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly
    Annamaria Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 157:579-87. 2007
    ..To evaluate the efficacy of dose escalation of Octreotide-long-acting repeatable (LAR) up to 40 mg/month we studied 56 newly diagnosed patients with acromegaly (24 women, 32 men; age 20-82 years)...
  28. ncbi Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
    A Colao
    Department of Molecular and Clinical Endocrinology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 85:193-9. 2000
    ..6%), diastolic filling abnormalities (69.2%), and impaired systolic function at rest (53.9%). A careful cardiac investigation should thus be performed in all acromegalic patients showing these complications...
  29. ncbi Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University Naples, Italy
    Clin Endocrinol (Oxf) 52:319-27. 2000
    ..To evaluate the effect of hyperprolactinaemia and its treatment with dopamine-agonists on bone mass and turnover in adolescent patients compared to adults...
  30. ncbi Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    N Engl J Med 349:2023-33. 2003
    ..We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients...
  31. pmc Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations
    Annamaria Colao
    Dipartimento di Medicina Clinica e Chirurgia, Universita di Napoli Federico II, Naples, Italy
    Pituitary 17:180-6. 2014
    ..Further research into hyperglycemia following pasireotide treatment will help refine the optimal strategy in Cushing's disease. ..
  32. pmc Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
    A Colao
    Dipartimento di Medicina Clinica e Chirurgia A C, Universita Federico II di Napoli, 80131 Naples, Italy Neuroendocrine Unit M D B, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, 3858 Jardim Paulista, Sao Paulo, Brazil Department of Medicine P F, Columbia University College of Physicians and Surgeons, New York, New York 10032 Department of Endocrinology F G, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China Department of Neurosurgery C C S, Taichung Veterans General Hospital, Taichung 40705, Taiwan Department of Physical Therapy C C S, Hungkuang University, Taichung 43302, Taiwan Department of Medicine and Tri Service General Hospital C C S, National Defense Medical Center, Taipei 11490, Taiwan Endocrine Unit M G, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 22421020, Brazil Department of Medicine and Neurological Surgery M F, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239 Department of Medicine A J v d L, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands Brain Research Imaging Centre A J F, University of Edinburgh, Korea
    J Clin Endocrinol Metab 99:791-9. 2014
    ..With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control...
  33. doi Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation
    Renata S Auriemma
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, I 80131 Napoli, Italy
    J Clin Endocrinol Metab 98:372-9. 2013
    ..The current survey study investigated the recurrence rate of hyperprolactinemia after cabergoline (CAB)-induced pregnancy and after lactation as well as safety of CAB exposure during early gestation...
  34. pmc Serum 25-Hydroxyvitamin D Levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS
    Silvia Savastano
    Department of Molecular and Clinical Endocrinology and Oncology, Division of Endocrinology, University Federico II of Naples, Via S, Pansini 5, Naples, 80131, Italy
    Nutr Metab (Lond) 8:84. 2011
    ..abstract:..
  35. pmc The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
    Anne Klibanski
    Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Pituitary 13:266-86. 2010
    ..Panel opinions, based on the level of available scientific evidence, were polled. Finally, their views were compared with those of surveyed community-based endocrinologists and neurosurgeons...
  36. pmc Relationship between heart rate recovery and inflammatory markers in patients with polycystic ovary syndrome: a cross-sectional study
    Francesco Giallauria
    Department of Clinical Medicine, Cardiovascular and Immunological Sciences, Cardiac Rehabilitation Unit, University of Naples Federico II, Naples, Italy
    J Ovarian Res 2:3. 2009
    ..A subclinical increase of the inflammation markers has been also observed in the PCOS. This study was designed to study the relationships between HRR and inflammatory markers in PCOS women...
  37. pmc Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
    Beverly Mk Biller
    Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, USA
    BMC Endocr Disord 10:10. 2010
    ....
  38. ncbi Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 90:2056-62. 2005
    ..These findings support the indication for GH replacement in severe GH deficiency adult patients...
  39. ncbi Growth hormone/insulin-like growth factor-I system and connective tissues: basic aspects and clinical implications
    Annamaria Colao
    Unit of Neuroendocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pancini C, Naples 80131, Italy
    Rheum Dis Clin North Am 31:29-42, viii. 2005
    ..This article reviews basic and clinical aspects of the effects of growth hormone and insulin-like growth factor-I on the connective tissues...
  40. doi Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Napoli, Italy
    J Clin Endocrinol Metab 93:3777-84. 2008
    ..Cabergoline, a dopamine receptor-2 agonist used to treat prolactinomas, was associated with increased risk of cardiac valve disease in Parkinson's disease...
  41. ncbi The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Napoli, Italy
    J Clin Endocrinol Metab 89:5998-6004. 2004
    ..5% of non-GHD, and 90% of controls. In conclusion, cardiac performance is correlated with the GH status because significant impairment was found in patients with severe and partial GHD but not in non-GHD hypopituitary patients...
  42. ncbi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 156:S57-63. 2007
    ..No data are available in other pituitary tumour histotypes. Preliminary observations in patients with clinically non-functioning adenomas are very promising...
  43. doi Medical therapy of pituitary adenomas: effects on tumor shrinkage
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Rev Endocr Metab Disord 10:111-23. 2009
    ..NFA respond very scantly to both DA and SSA even if receptors targeting these drugs are present. Whether this is due to limited receptor number or alterations of post-receptor pathway is still unknown...
  44. ncbi Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 68:66-71. 2008
    ..Although cabergoline has been used to treat hyperprolactinaemia since the mid-1990s, safety data related to maternal and foetal exposure to this agent are still limited...
  45. ncbi Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Clin Endocrinol (Oxf) 61:360-6. 2004
    ..To investigate the role of IGF-1 on intima-media thickness (IMT) at common carotid arteries by Doppler ultrasonography...
  46. ncbi The heart: an end-organ of GH action
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 151:S93-101. 2004
    ..These beneficial effects appear earlier in young patients with short disease duration than in elderly patients. In conclusion, GH and IGF-I play a main role in the regulation of cardiac development and performance...
  47. ncbi The role of somatostatin and dopamine receptors as molecular targets for the treatment of patients with pituitary adenomas
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Eur J Endocrinol 156:S1. 2007
  48. doi Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:528-37. 2009
    ..The aim of the study was to investigate the 5-yr impact of surgery and somatostatin analogs (SSA) on glucose metabolism in acromegaly...
  49. doi Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 71:237-45. 2009
    ..To evaluate GH and IGF-I control and tumour shrinkage in newly diagnosed patients with acromegaly treated first-line with lanreotide-Autogel (ATG) 120 mg. Design Open, prospective...
  50. ncbi Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II, Naples, Italy
    Nat Clin Pract Endocrinol Metab 2:200-10. 2006
    ..Fewer results are available for men than for women, but there is no evidence that men are less responsive to dopamine agonists than are women...
  51. ncbi Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 93:3416-24. 2008
    ..Severe GH deficiency (GHD) is associated with, increased cardiovascular risk and intima-media thickness (IMT) at major arteries...
  52. ncbi No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, Naples, Italy
    J Clin Endocrinol Metab 93:2243-8. 2008
    ..Excess GH and IGF-I in acromegaly are associated with reduced life expectancy due to cardiovascular complications...
  53. ncbi The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via S Pansini 5, 80131 Napoli, Italy
    J Clin Endocrinol Metab 91:2191-200. 2006
    ..Partial GH deficiency (GHD) in adults is poorly studied...
  54. ncbi The acromegalic arthropathy
    A Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology, Federico II, University of Naples, Naples, Italy
    J Endocrinol Invest 28:24-31. 2005
    ..Arthropathy can be reversed by normalizing GH and IGF-I levels only at the initial stage. If the disease is left untreated for long time, the osteo-articular sequelae cannot be modified by any treatment of acromegaly...
  55. doi Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, Naples, Italy
    J Clin Endocrinol Metab 93:2639-46. 2008
    ..The objective of the study was to investigate whether first-line surgery or somatostatin analogs (SSA) have a different outcome on cardiomyopathy after 12 months...
  56. doi GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 69:613-20. 2008
    ..Approximately one-third of patients with acromegaly have concomitant hypertension. The outcome of hypertension after treatment of acromegaly is unknown...
  57. ncbi Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly
    Annamaria Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 63:342-9. 2005
    ..GH and IGF-I secretion is related to gender and age...
  58. ncbi Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Italy
    Eur J Endocrinol 154:467-77. 2006
    ..We aimed to investigate the efficacy of pegvisomant in patients with acromegaly resistant to long-term (> or = 24-month), high-dose treatment with octreotide-LAR (40 mg/month) or lanreotide (120 mg/month)...
  59. ncbi New perspectives in the medical treatment of acromegaly
    A Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Endocrinol Invest 28:58-66. 2005
    ..These drugs have been also shown to possess strong GH-inhibitory activity in primary cultures from GH-secreting adenomas. These drugs are the future perspectives in the treatment of patients with GH-secreting or GH/PRL-secreting tumors...
  60. ncbi Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    J Endocrinol Invest 28:440-8. 2005
    ..Our results support a role of the IGF/IGFBP-3 axis in the pathogenesis of atherosclerosis...
  61. ncbi Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 93:3436-42. 2008
    ..The objective of the study was to evaluate whether tumor shrinkage or GH and IGF-I levels achieved after 3 months predicted tumor shrinkage after 12 months of octreotide-long-acting release (LAR) treatment...
  62. ncbi Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80123 Naples, Italy
    Growth Horm IGF Res 16:S41-8. 2006
    ..This review discusses the roles of GHD and GH replacement therapy in the development of cardiovascular disease...
  63. ncbi Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH defici
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 90:5146-55. 2005
    ..GH secretion and response to GH replacement are gender-related...
  64. ncbi Influence of growth hormone on cardiovascular health and disease
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Treat Endocrinol 2:347-56. 2003
    ..Although these data need to be confirmed in more extensive studies, such promising results open new perspectives for somatropin therapy. The role of GH secretagogues in heart failure is still unknown...
  65. ncbi Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide
    A Colao
    Departments of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples Nuclear Medicine, National Cancer Institute, Fondazione G Pascale, Naples, Italy
    Clin Endocrinol (Oxf) 52:437-45. 2000
    ..Dopamine agonists are indicated as primary therapy for PRL-secreting pituitary adenomas, while controversial results have been reported in nonfunctioning adenomas (NFA)...
  66. ncbi Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 91:85-92. 2006
    ..Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant...
  67. doi Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 70:757-68. 2009
    ..This prospective randomized study evaluated the efficacy and safety of octreotide LAR vs. surgery in newly diagnosed acromegalic patients...
  68. ncbi Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients
    A Colao
    Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 85:3754-61. 2000
    ..These data suggest that hyperplasia, but not cancer, is frequent in acromegalic men, and that the GH-IGF axis and age are independently associated with the development of this process...
  69. ncbi Cabergoline
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Expert Opin Pharmacother 1:555-74. 2000
    ..CAB was also reported to have some efficacy in patients with Nelson's syndrome and Cushing's disease although these data are available only for limited case reports...
  70. ncbi Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 54:515-24. 2001
    ..Despite the increasing evidence for the existence of a specific cardiomyopathy in acromegaly, the presence of vascular abnormalities has been never investigated...
  71. doi Pituitary carcinomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology, Federico II University of Naples, Naples, Italy
    Front Horm Res 38:94-108. 2010
    ....
  72. ncbi Somatostatin analogues: treatment of pituitary and neuroendocrine tumors
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy
    Prog Brain Res 182:281-94. 2010
    ..A recent study has also demonstrated a beneficial effect of OCT long-acting release in patients with non-functioning NETs independently from their progression status. These data open the treatment with SSAs in all NET patients...
  73. doi Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University Federico II of Naples, Naples, Italy
    Clin Endocrinol (Oxf) 74:234-40. 2011
    ..Design  Analytical, retrospective...
  74. ncbi Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via Sergio Pansini 5, 80131, Naples, Italy
    Eur J Endocrinol 146:303-9. 2002
    ..4 +/- 12.6 mU/l, IGF--I=866.0 +/- 55.8 microg/l) and 24 healthy subjects sex-, age- and body mass index-matched with the patients (as controls)...
  75. ncbi The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:1088-93. 2002
    ..A similar period of GH deprivation induced a further impairment of lipid profile and cardiac performance. This finding strongly supports the need of GH replacement in adult GHD patients...
  76. ncbi Dopamine receptor agonists for treating prolactinomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    Expert Opin Investig Drugs 11:787-800. 2002
    ..The great efficacy of this compound together with its excellent tolerability makes this drug the current treatment of choice for the majority of patients with hyperprolactinaemic disorders...
  77. ncbi Growth hormone and the heart
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Clin Endocrinol (Oxf) 54:137-54. 2001
    ..Although these data need to be confirmed in more extensive studies, such promising results seem to open new perspectives for GH treatment in humans...
  78. ncbi Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 85:3132-40. 2000
    ..The sustained suppression of IGF-I levels was followed by a significant reduction of LVMi in all patients already after 3 months of treatment, with recovery of LV hypertrophy in 6 of 11 patients. (ABSTRACT TRUN..
  79. doi Prolactinomas in children and adolescents
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Endocr Dev 17:146-59. 2010
    ..Radiotherapy should be limited to the cases with aggressive tumors, nonresponsive to dopamine agonists, because of the risk of neurological damage and hypopituitarism later in the lives of these patients...
  80. ncbi The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 84:1277-82. 1999
    ....
  81. ncbi Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 84:1919-24. 1999
    ..These abnormalities were consistently present in all patients with GHD regardless of the presence of additional hormone deficits, suggesting that GHD plays a central role in the development of osteopenia in hypopituitary patients...
  82. ncbi Impaired cardiac performance in elderly patients with growth hormone deficiency
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 84:3950-5. 1999
    ..614; P < 0.05) and with systolic and diastolic blood pressures both at rest (r = 0.745; P < 0.01 and r = 0.650; P < 0.05) and at peak exercise (r = 0.684; P < 0.05 and r =..
  83. ncbi Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months
    A Colao
    Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    Clin Endocrinol (Oxf) 51:611-8. 1999
    ..A major cause of morbidity and functional disability in acromegaly is represented by axial and peripheral arthropathy...
  84. ncbi Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients
    A Colao
    Department of Molecular and Clinical Endocrinology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 85:2247-52. 2000
    ..In conclusion, the prevalence of macroprolactinoma shrinkage after CAB treatment at standard doses for 1-3 yr was higher in naive patients (92.3%) than in intolerant (42.1%), resistant (30.3%), and responsive patients (38.4%). Thus, C..
  85. doi Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study
    Annamaria Colao
    Section of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S Pansini 5, 80131 Naples, Italy
    Eur J Endocrinol 165:713-21. 2011
    ..The most frequent cause of death in acromegaly is cardiomyopathy...
  86. ncbi Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure
    A Colao
    Department of Molecular and Clinical Endocrinology, Federico II University, Naples, Italy
    J Clin Endocrinol Metab 84:2664-72. 1999
    ....
  87. ncbi (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, University Federico II of Naples, Italy
    Clin Endocrinol (Oxf) 56:713-21. 2002
    ....
  88. ncbi Cardiovascular consequences of early-onset growth hormone excess
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:3097-104. 2002
    ..These deleterious effects of early-onset acromegaly are ameliorated by suppressing GH/IGF-I levels for 6 months...
  89. ncbi Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Via S Pansini 5, Naples, Italy
    J Clin Endocrinol Metab 94:2907-14. 2009
    ..The objective of the study was to investigate the impact of first-line somatostatin analogs (SSAs) on glucose tolerance (GT) in acromegaly...
  90. ncbi Systemic complications of acromegaly: epidemiology, pathogenesis, and management
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    Endocr Rev 25:102-52. 2004
    ..Finally, the most important cause of morbidity and functional disability of the disease is arthropathy, which can be reversed at an initial stage, but not if the disease is left untreated for several years...
  91. ncbi A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology, Section of Endocrinology, University of Naples Federico II, Italy, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:4414-22. 2009
    ..The objective of the study was to reevaluate the diagnostic accuracy of GH peak after GHRH plus arginine test (GHRH+ARG) according to patients' age, body mass index (BMI), and waist circumference to diagnose GH deficiency (GHD)...
  92. ncbi Hypothalamic-pituitary-gonadal axis function after successful kidney transplantation in men and women
    Libuse Tauchmanova
    Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Cantazaro, Italy
    Hum Reprod 19:867-73. 2004
    ..Renal transplantation (RT) is the most common solid organ transplant procedure. Several studies have reported on gonadal function in male and female RT recipients with controversial results...
  93. ncbi Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
    Endocrine 20:279-83. 2003
    ..No evident effect of tumor shrinkage has been reported. At present, the use of somatostatin analogs in clinically nonfunctioning adenomas is questioned...
  94. ncbi Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, University Federico II of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 89:2770-5. 2004
    ..In conclusion, in young men with prolactinoma PRL excess is unlikely to have effects on the prostate per se, because it is accompanied by low testosterone and DHT levels that produce the major effects...
  95. ncbi Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients
    Annamaria Colao
    Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Italy
    J Clin Endocrinol Metab 88:88-94. 2003
    ..In these cases, GH replacement might be performed sequentially to reduce the hypertrophic effect of combining GH and testosterone...
  96. ncbi The treatment algorithm of acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, Federico II University, Naples, Italy
    J Endocrinol Invest 26:39-45. 2003
  97. doi 5 Long-term acromegaly and associated cardiovascular complications: a case-based review
    Annamaria Colao
    Universita degli Studi di Napoli Federico II, Department of Molecular and Clinical Endocrinology and Oncology, Via S Pansini 5, 80131 Napoli, Italy
    Best Pract Res Clin Endocrinol Metab 23:S31-8. 2009
    ..The roles of surgery and medical treatment are discussed in the context of using optimal treatment strategies to help reverse cardiac hypertrophy and normalize other cardiac risk factors...
  98. ncbi Gender- and age-related differences in the endocrine parameters of acromegaly
    A Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
    J Endocrinol Invest 25:532-8. 2002
    ..Women have lower IGF-I levels but higher GH nadir after glucose load than men. These age and gender differences should be considered to appropriately evaluate the activity of acromegaly throughout a life-span...
  99. ncbi Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study
    Annamaria Colao
    Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, 80131 Naples, Italy
    J Clin Endocrinol Metab 94:3746-56. 2009
    ..The objective of the study was to evaluate the efficacy of 5 yr of depot somatostatin analogs (SSAs) as first-line therapy in acromegaly...
  100. ncbi In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy
    D Ferone
    Department of Molecular and Clinical Endocrinology, Federico II, University of Naples, Italy
    Clin Endocrinol (Oxf) 54:469-77. 2001
    ..The new potent DA might be primarily considered in the medical treatment of hyperprolactinemic acromegalics, while SA alone or in combination with DA in case of ineffective hormone suppression...